Filter results by

Search Help
Currently selected filters that can be removed

Keyword(s)

Year of publication

4 facets displayed. 0 facets selected.

Author(s)

1 facets displayed. 1 facets selected.

Survey or statistical program

2 facets displayed. 0 facets selected.
Sort Help
entries

Results

All (10)

All (10) ((10 results))

  • Articles and reports: 88F0006X2005010
    Description:

    This paper looks into Canadian innovative biotechnology firms' access to financing capital. Results show that over 70% of biotech firms that attempted to raise financing capital were successful. Funds were primarily sought for R&D activities and came primarily from Canadian venture capitalists. Harsher market conditions were the main reasons put forward by investors to limit or reject biotechnology firms' funding requests.

    Release date: 2005-04-29

  • Articles and reports: 88-003-X20040016791
    Geography: Canada, Province or territory
    Description:

    Data from the 2001 Biotechnology Use and Development Survey reveal that there are 133 biotechnology Canadian-based firms manufacturing or developing bioproducts. These mostly private 'home-grown' firms, located in Quebec, British Columbia and Ontario, are operating across all economic sectors. The largest share of their combined portfolio of 805 bioproducts is at the commercialization stage. Bioprocessing-based bioproducts (products developed or made using enzymes and bacteria culture) lead the way.

    Release date: 2004-03-05

  • Articles and reports: 88F0006X2004006
    Description:

    Biotechnology is a pervasive technology used in several industrial sectors, making collecting sound data a real challenge. This paper describes the methodology of the Biotechnology Use and Development Survey. Some of the specific issues dealt with are the definitions of biotechnology and innovative biotechnology firms, the target population, sampling, data collection procedures, and data quality evaluation.

    Release date: 2004-03-05

  • Articles and reports: 88F0006X2003013
    Description:

    This paper used data from the 2001 Biotechnology Use and Development Survey (BUDS) to look into bioproduct development using biotechnologies. Results show that the development of bioproducts has become an intrinsic part of the activities of Canadian biotechnology firms.

    Release date: 2003-12-08

  • Articles and reports: 88-003-X20030026570
    Geography: Canada
    Description:

    In 2001, Canadian biotech firms raised $980 million in financing capital, a sharp drop from the $2.1 billion raised in 1999. Overall, 114 firms out of 188 (61%) that attempted to raise capital either failed or did not reach their targets. Why are biotech firms encountering difficulties in raising financing capital?

    Release date: 2003-06-27

  • Articles and reports: 88F0006X2003003
    Description:

    Results show that biotechnology companies in Canada are experiencing rapid growth and that Statistics Canada is now capturing more biotechnology activity. For example, between 1997 and 1999, Canadian biotechnology firms grew in number with core biotechnology firms increasing from 282 firms to 358. They brought in $1.9 billion in biotechnology revenues in 1999, compared with $813 million in 1997; they spent around $827 million on biotechnology research and development in 1999, compared with $494 million in 1997.

    Release date: 2003-03-10

  • Articles and reports: 88-003-X20030016475
    Geography: Canada
    Description:

    Data from the 2001 Biotechnology Use and Development Survey show that human resources in biotechnology increased substantially between 1999 and 2001. In this article, we attempt to answer two questions: What are the characteristics of the human resources engaged in the biotechnology field in Canada? Moreover, what are the main factors that contributed to the growth of these human resources in 2001?

    Release date: 2003-02-18

  • Articles and reports: 88-003-X20030016476
    Geography: Canada
    Description:

    Canadian biotechnology is gaining momentum. More firms are getting their products onto the markets and increasing revenues. With the human health sector leading the way, biotechnology revenues rose by a massive 343% for the 1997 to 2001 period, reaching $3.5 billion in 2001. During this same period, the number of firms increased by 33%.

    Release date: 2003-02-18

  • Articles and reports: 88-003-X20010035972
    Geography: Canada
    Description:

    Based on information from the 1997 Biotechnology Firm Survey, we know biotechnology firms generated $813 million in biotech revenues; employed 9,000 people in biotech-related activities and had almost 9,000 products across all stages of development. Explore issues such as - What are the main features of this sector? What is the extent of networking activities by the firms? And what kinds of problems are they facing when selling their products?

    Release date: 2001-10-31

  • Articles and reports: 88F0006X2001012
    Description:

    As of 1997, Canadian biotech industry was made of 282 core firms. Of these, 214 were small firms with less than 50 employees, 37 were medium firms with 51 to 150 employees, and 31 were large firms with over 150 employees. They earned $813 million from biotech products sales, $311 million of which were from exports. They employed 9,000 people in biotech related activities and had 8,924 products at all stages of development. Private placements, venture capital and labour sponsored funds were these firms main sources of financing capital. Access to capital was the most serious obstacle faced by the biotech firms in 1997. Marketing and distribution were their major reasons for entertaining strategic alliances, while universities were their most preferred R&D partners.

    Release date: 2001-09-25
Stats in brief (0)

Stats in brief (0) (0 results)

No content available at this time.

Articles and reports (10)

Articles and reports (10) ((10 results))

  • Articles and reports: 88F0006X2005010
    Description:

    This paper looks into Canadian innovative biotechnology firms' access to financing capital. Results show that over 70% of biotech firms that attempted to raise financing capital were successful. Funds were primarily sought for R&D activities and came primarily from Canadian venture capitalists. Harsher market conditions were the main reasons put forward by investors to limit or reject biotechnology firms' funding requests.

    Release date: 2005-04-29

  • Articles and reports: 88-003-X20040016791
    Geography: Canada, Province or territory
    Description:

    Data from the 2001 Biotechnology Use and Development Survey reveal that there are 133 biotechnology Canadian-based firms manufacturing or developing bioproducts. These mostly private 'home-grown' firms, located in Quebec, British Columbia and Ontario, are operating across all economic sectors. The largest share of their combined portfolio of 805 bioproducts is at the commercialization stage. Bioprocessing-based bioproducts (products developed or made using enzymes and bacteria culture) lead the way.

    Release date: 2004-03-05

  • Articles and reports: 88F0006X2004006
    Description:

    Biotechnology is a pervasive technology used in several industrial sectors, making collecting sound data a real challenge. This paper describes the methodology of the Biotechnology Use and Development Survey. Some of the specific issues dealt with are the definitions of biotechnology and innovative biotechnology firms, the target population, sampling, data collection procedures, and data quality evaluation.

    Release date: 2004-03-05

  • Articles and reports: 88F0006X2003013
    Description:

    This paper used data from the 2001 Biotechnology Use and Development Survey (BUDS) to look into bioproduct development using biotechnologies. Results show that the development of bioproducts has become an intrinsic part of the activities of Canadian biotechnology firms.

    Release date: 2003-12-08

  • Articles and reports: 88-003-X20030026570
    Geography: Canada
    Description:

    In 2001, Canadian biotech firms raised $980 million in financing capital, a sharp drop from the $2.1 billion raised in 1999. Overall, 114 firms out of 188 (61%) that attempted to raise capital either failed or did not reach their targets. Why are biotech firms encountering difficulties in raising financing capital?

    Release date: 2003-06-27

  • Articles and reports: 88F0006X2003003
    Description:

    Results show that biotechnology companies in Canada are experiencing rapid growth and that Statistics Canada is now capturing more biotechnology activity. For example, between 1997 and 1999, Canadian biotechnology firms grew in number with core biotechnology firms increasing from 282 firms to 358. They brought in $1.9 billion in biotechnology revenues in 1999, compared with $813 million in 1997; they spent around $827 million on biotechnology research and development in 1999, compared with $494 million in 1997.

    Release date: 2003-03-10

  • Articles and reports: 88-003-X20030016475
    Geography: Canada
    Description:

    Data from the 2001 Biotechnology Use and Development Survey show that human resources in biotechnology increased substantially between 1999 and 2001. In this article, we attempt to answer two questions: What are the characteristics of the human resources engaged in the biotechnology field in Canada? Moreover, what are the main factors that contributed to the growth of these human resources in 2001?

    Release date: 2003-02-18

  • Articles and reports: 88-003-X20030016476
    Geography: Canada
    Description:

    Canadian biotechnology is gaining momentum. More firms are getting their products onto the markets and increasing revenues. With the human health sector leading the way, biotechnology revenues rose by a massive 343% for the 1997 to 2001 period, reaching $3.5 billion in 2001. During this same period, the number of firms increased by 33%.

    Release date: 2003-02-18

  • Articles and reports: 88-003-X20010035972
    Geography: Canada
    Description:

    Based on information from the 1997 Biotechnology Firm Survey, we know biotechnology firms generated $813 million in biotech revenues; employed 9,000 people in biotech-related activities and had almost 9,000 products across all stages of development. Explore issues such as - What are the main features of this sector? What is the extent of networking activities by the firms? And what kinds of problems are they facing when selling their products?

    Release date: 2001-10-31

  • Articles and reports: 88F0006X2001012
    Description:

    As of 1997, Canadian biotech industry was made of 282 core firms. Of these, 214 were small firms with less than 50 employees, 37 were medium firms with 51 to 150 employees, and 31 were large firms with over 150 employees. They earned $813 million from biotech products sales, $311 million of which were from exports. They employed 9,000 people in biotech related activities and had 8,924 products at all stages of development. Private placements, venture capital and labour sponsored funds were these firms main sources of financing capital. Access to capital was the most serious obstacle faced by the biotech firms in 1997. Marketing and distribution were their major reasons for entertaining strategic alliances, while universities were their most preferred R&D partners.

    Release date: 2001-09-25
Journals and periodicals (0)

Journals and periodicals (0) (0 results)

No content available at this time.

Date modified: